An interview discussing recent research on the association between GLP-1 receptor agonist use and the risk of atrial fibrillation.

Big shifts GLP-1 market include FDA approval of oral weight loss drugs and expanded Medicare coverage starting July 2024 for key GLP-1 therapies.

Dr. Angela Fitch, co-founder and chief medical officer of knownwell, a "weight-inclusive" healthcare company based in Boston, said she would caution against labeling any medication as an "everything ...

Rates of overweight and obesity have more than doubled in the United States during the last three decades, according to a new analysis. By 2050, it’s anticipated that 213 million adults (age, > 25 ...

GLP-1 weight-loss drugs are everywhere online — but some buyers are getting them from the gray market without ever seeing a ...

The UC Davis Innovation Institute for Food and Health recently hosted scientists, physicians and industry experts to discuss how drugs based on GLP-1 are transforming treatment for obesity, diabetes ...

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking ...

The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task ...